公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United Statesand Rest of the World, of which United States generates majority of the revenue.
公司地址 1000 Spring Street, Silver Spring, MD, USA, 20910
電話號碼 +1 301 608-9292
傳真號碼 +1 301 608-9291
公司網頁 https://www.unither.com
員工數量 1400
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Martine A. Rothblatt, J.D.,M.B.A.,PhD Chairperson of the Board and Chief Executive Officer 美元 1.51M 25/02/2026
Mr. Paul A. Mahon,J.D. Executive Vice President, General Counsel and Corporate Secretary 美元 940.00K 25/02/2026
Mr. James C. Edgemond Chief Financial Officer, Principal Accounting Officer and Treasurer 美元 860.58K 25/02/2026
Mr. Michael Benkowitz President and Chief Operating Officer 美元 1.19M 25/02/2026
 
董事會成員
董事會 職務 更新日期
Mr. Christopher Patusky,J.D. Vice Chairman of the Board and Lead Independent Director 25/02/2026
Dr. Louis W. Sullivan, M.D. Independent Director 25/02/2026
Mr. Raymond Dwek,F.R.S. Independent Director 25/02/2026
Mr. Raymond C. Kurzweil Independent Director 25/02/2026
Mr. Kevin J. Tracey, M.D. Director 22/01/2026
Governor Tommy G. Thompson, J.D. Independent Director 25/02/2026
Mr. Christopher Causey,M.B.A. Independent Director 25/02/2026
Dr. Martine A. Rothblatt, J.D.,M.B.A.,PhD Chairperson of the Board and Chief Executive Officer 25/02/2026
Mr. Richard Giltner Independent Director 25/02/2026
Ms. Jan Malcolm Independent Director 25/02/2026
Dr. Judy D. Olian, PhD Independent Director 25/02/2026
Ms. Nilda Mesa, J.D. Independent Director 25/02/2026
Dr. Linda Maxwell, M.B.A.,M.D. Independent Director 25/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:04)
代號 名稱 佔比% 持有日期
IJHiShares Core S&P Mid-Cap ETF3.17%28/02/2026
XMHQInvesco S&P MidCap Quality ETF0.84%27/02/2026
MDYState Street® SPDR® S&P MIDCAP 400® ETF0.71%31/01/2026
IBBiShares Biotechnology ETF0.71%28/02/2026
IJKiShares S&P Mid-Cap 400 Growth ETF0.54%28/02/2026
EMMState Street SPDR Port S&P 400 Md CpETF0.47%27/02/2026
XBIState Street® SPDR® S&P® Biotech ETF0.46%27/02/2026
FBTFirst Trust NYSE Arca Biotech ETF0.38%26/02/2026
IWRiShares Russell Mid-Cap ETF0.36%28/02/2026
VFLOVictoryShares Free Cash Flow ETF0.35%27/02/2026
VHTVanguard Health Care ETF0.30%31/01/2026
COWZPacer US Cash Cows 100 ETF0.29%27/02/2026
SCHMSchwab US Mid-Cap ETF™0.27%28/02/2026
IWDiShares Russell 1000 Value ETF0.21%28/02/2026
USMViShares MSCI USA Min Vol Factor ETF0.19%28/02/2026
QUALiShares MSCI USA Quality Factor ETF0.18%28/02/2026
IVOOVanguard S&P Mid-Cap 400 ETF0.15%31/01/2026
MDYGState Street® SPDR® S&P 400™ Md Cp GrETF0.14%27/02/2026
DFACDimensional US Core Equity 2 ETF0.14%27/02/2026
FTGSFirst Trust Growth Strength ETF0.13%26/02/2026
 1    2  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.